4,073 results match your criteria Progressive Supranuclear Palsy


A rare cause of axial worsening in Parkinson's disease: A case of myasthenic pseudo-parkinsonism.

Clin Neurol Neurosurg 2019 Feb 11;179:1-3. Epub 2019 Feb 11.

Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2019.02.009DOI Listing
February 2019

A walk through tau therapeutic strategies.

Acta Neuropathol Commun 2019 Feb 15;7(1):22. Epub 2019 Feb 15.

AXON Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia.

Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease and related human tauopathies. There is a growing body of evidence indicating that pathological tau species can travel from cell to cell and spread the pathology through the brain. Throughout the last decade, physiological and pathological tau have become attractive targets for AD therapies. Read More

View Article

Download full-text PDF

Source
https://actaneurocomms.biomedcentral.com/articles/10.1186/s4
Publisher Site
http://dx.doi.org/10.1186/s40478-019-0664-zDOI Listing
February 2019
3 Reads

Dementia spectrum disorders: lessons learnt from decades with PET research.

J Neural Transm (Vienna) 2019 Feb 14. Epub 2019 Feb 14.

Neurodegeneration Imaging Group, Maurice Wohl Clinical Neuroscience Institute, 125 Coldharbour Lane, Camberwell, London, SE5 9NU, UK.

The dementia spectrum encompasses a range of disorders with complex diagnosis, pathophysiology and limited treatment options. Positron emission tomography (PET) imaging provides insights into specific neurodegenerative processes underlying dementia disorders in vivo. Here we focus on some of the most common dementias: Alzheimer's disease, Parkinsonism dementias including Parkinson's disease with dementia, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal syndrome, and frontotemporal lobe degeneration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-019-01975-4DOI Listing
February 2019
1 Read

Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.

Mov Disord 2019 Feb 13. Epub 2019 Feb 13.

Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.

Background: No prospective study of patients with Parkinson's disease (PD) has investigated the appearance of vertical gaze abnormalities, a feature suggestive of progressive supranuclear palsy (PSP).

Objective: To identify, within a cohort of patients with an initial diagnosis of PD, those who developed vertical gaze abnormalities during a 4-year follow-up, and to investigate the performance of new imaging biomarkers in predicting vertical gaze abnormalities.

Methods: A total of 110 patients initially classified as PD and 74 controls were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27621DOI Listing
February 2019
1 Read

Multimodal MRI evaluation of parkinsonian limbic pathologies.

Neurobiol Aging 2019 Jan 16;76:194-200. Epub 2019 Jan 16.

Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Pharmacology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Radiology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Neurosurgery, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Kinesiology, Penn State University-Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address:

Previous multimodal magnetic resonance imaging (MRI) studies of parkinsonian syndromes have focused primarily on motor-related basal ganglia structures. The present study investigated MRI changes in nonmotor-related limbic structures in 35 Parkinson's disease, 16 multiple system atrophy parkinsonian subtype, 17 progressive supranuclear palsy, and 37 control subjects. Mean diffusivity (MD), fractional anisotropy, transverse relaxation rate (R2*), quantitative susceptibility mapping, and volume measurements were obtained from the amygdala, hippocampus, and nucleus accumbens (NAc) to examine differences between groups and to test for associations with clinical scores. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2019.01.004DOI Listing
January 2019
1 Read

Abnormal Eye Movements in Parkinsonism and Movement Disorders.

J Mov Disord 2019 Jan 30;12(1):1-13. Epub 2019 Jan 30.

Department of Neurology, Korea University College of Medicine, Korea University Ansan Hospital, Ansan.

Abnormal eye movements are commonly observed in movement disorders. Ocular motility examination should include bedside evaluation and laboratory recording of ocular misalignment, involuntary eye movements, including nystagmus and saccadic intrusions/oscillations, triggered nystagmus, saccades, smooth pursuit (SP), and the vestibulo-ocular reflex. Patients with Parkinson's disease (PD) mostly show hypometric saccades, especially for the selfpaced saccades, and impaired SP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14802/jmd.18034DOI Listing
January 2019

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Mov Disord 2019 Feb 6. Epub 2019 Feb 6.

Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA.

Background: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times.

Methods: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27619DOI Listing
February 2019
1 Read

Heritability in frontotemporal tauopathies.

Alzheimers Dement (Amst) 2019 Dec 24;11:115-124. Epub 2019 Jan 24.

Faculty of Medicine and Health, Charles Perkins Centre and Discipline of Pathology, University of Sydney, Sydney, Australia.

Introduction: Exploring the degree of heritability in a large cohort of frontotemporal lobar degeneration with tau-immunopositive inclusions (FTLD-tau) and determining if different FTLD-tau subtypes are associated with stronger heritability will provide important insight into disease pathogenesis.

Methods: Using modified Goldman pedigree classifications, heritability was examined in pathologically proven FTLD-tau cases with dementia at any time (n = 124) from the Sydney-Cambridge collection.

Results: Thirteen percent of the FTLD-tau cohort have a suggested autosomal dominant pattern of inheritance, 25% have some family history, and 62% apparently sporadic. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23528729183008
Publisher Site
http://dx.doi.org/10.1016/j.dadm.2018.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351353PMC
December 2019
2 Reads

The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations.

Front Neurol 2019 22;10. Epub 2019 Jan 22.

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Differentiating idiopathic Parkinson's disease (IPD) from atypical Parkinsonian disorders (APD) is challenging, especially in early disease stages. Postural instability and gait difficulty (PIGD) are substantial motor impairments of IPD and APD. Clinical evidence implies that patients with APD have larger PIGD impairment than IPD patients. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2019.00005
Publisher Site
http://dx.doi.org/10.3389/fneur.2019.00005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349719PMC
January 2019
2 Reads

Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.

J Clin Exp Neuropsychol 2019 Feb 4:1-7. Epub 2019 Feb 4.

b Memory and Aging Center, Department of Neurology , University of California , San Francisco , CA, USA.

Progressive supranuclear palsy (PSP) is associated with a variety of cognitive deficits, as well as motor and psychiatric disturbances. As clinical trials for PSP evolve, briefer screening instruments will be needed to determine cognitive effects of interventions. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) may fill this gap. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13803395.2019.1572073DOI Listing
February 2019

Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.

J Neuroimmune Pharmacol 2019 Jan 31. Epub 2019 Jan 31.

Department of Biomedical Sciences, Parkinson's Disorder Research Program, Iowa Center for Advanced Neurotoxicology, Iowa State University, Ames, IA, 50011, USA.

Adult-onset neurodegenerative disorders, like Parkinson's disease (PD) and dementia with Lewy bodies (DLB), that share the accumulation of aggregated α-synuclein (αSyn) as their hallmark molecular pathology are collectively known as α-synucleinopathies. Diagnosing α-synucleinopathies requires the post-mortem detection of αSyn in various brain regions. Recent efforts to measure αSyn in living patients include quantifying αSyn in different biofluids as a biomarker for PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11481-019-09835-4DOI Listing
January 2019
1 Read

Aluminum in Neurological and Neurodegenerative Disease.

Mol Neurobiol 2019 Jan 31. Epub 2019 Jan 31.

Russian Academy of Medical Sciences, Moscow, 113152, Russia.

With continuing cooperation from 18 domestic and international brain banks over the last 36 years, we have analyzed the aluminum content of the temporal lobe neocortex of 511 high-quality human female brain samples from 16 diverse neurological and neurodegenerative disorders, including 2 groups of age-matched controls. Temporal lobes (Brodmann areas A20-A22) were selected for analysis because of their availability and their central role in massive information-processing operations including efferent-signal integration, cognition, and memory formation. We used the analytical technique of (i) Zeeman-type electrothermal atomic absorption spectrophotometry (ETAAS) combined with (ii) preliminary analysis from the advanced photon source (APS) hard X-ray beam (7 GeV) fluorescence raster-scanning (XRFR) spectroscopy device (undulator beam line 2-ID-E) at the Argonne National Laboratory, US Department of Energy, University of Chicago IL, USA. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12035-018-1441-x
Publisher Site
http://dx.doi.org/10.1007/s12035-018-1441-xDOI Listing
January 2019
5 Reads

FDG-PET patterns associated with underlying pathology in corticobasal syndrome.

Neurology 2019 Jan 30. Epub 2019 Jan 30.

From the Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (M.P., F.N.) and Health Sciences (S.M.), University of Genoa; IRCCS Ospedale Policlinico San Martino (M.P., S.M., F.N.), Genoa, Italy; Cognitive Neuroscience Division, Department of Neurology (E.D.H.), Gertrude H. Sergievsky Center, New York; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (E.D.H., W.C.K.), Columbia University Medical Center, New York, NY; Department of Neurology (S.S.), UCSF Memory and Aging Center, UCSF, San Francisco, CA; Department of Pathology and Laboratory Medicine (S.S., B.G.), Indiana University School of Medicine, Indianapolis; Nuclear Medicine Unit (S.M.), IRCCS AOU San Martino, IST, Genoa, Italy; Behavioral Neurology Unit (E.M.W.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Psychiatry and Behavioral Sciences & Cognitive Neurology/Alzheimer's Disease Research Center (J.G.), Feinberg School of Medicine and Department of Psychology, Northwestern University; and Brain Injury Research, Cognitive Neuroscience Lab, Think and Speak Lab (J.G.), Shirley Ryan AbilityLab, Chicago, IL.

Objective: To evaluate brain Fluorodeoxyglucose PET (FDG-PET) differences among patients with a clinical diagnosis of corticobasal syndrome (CBS) and distinct underling primary pathologies.

Methods: We studied 29 patients with a diagnosis of CBS who underwent FDG-PET scan and postmortem neuropathologic examination. Patients were divided into subgroups on the basis of primary pathologic diagnosis: CBS-corticobasal degeneration (CBS-CBD) (14 patients), CBS-Alzheimer disease (CBS-AD) (10 patients), and CBS-progressive supranuclear palsy (CBS-PSP) (5 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007038DOI Listing
January 2019

Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism.

Am J Nucl Med Mol Imaging 2018 20;8(6):360-372. Epub 2018 Dec 20.

Department of Nuclear Medicine, Kyungpook National University Hospital Daegu, Republic of Korea.

Combined use of F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) for dopamine transporter imaging and F-fludeoxyglucose (FDG) for glucose metabolism shows good diagnostic performance for differential diagnosis of Parkinson disease (PD) and Parkinson plus syndrome (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies). A recent study showed that F-FP-CIT positron emission tomography (PET) with early perfusion imaging is useful for the differential diagnosis of PD and Parkinson plus syndrome with lower radiation exposure, time, and cost. In this review, we summarize the advantages of using F-FP-CIT PET for perfusion and dopamine transporter imaging, as well as clinical features useful for the differential diagnosis of PD and Parkinson plus syndrome. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334208PMC
December 2018
2 Reads

Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease.

Curr Opin Neurol 2019 Jan 28. Epub 2019 Jan 28.

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Institut de Neurociències Centro de Investigación Biomedica en Red Enfermedades Neurodegenerativas (CIBERNED).

Purpose Of Review: Anti-IgLON5 disease is a novel entity characterized by a distinctive sleep disorder associated with a variety of neurological symptoms, antibodies against IgLON5, and pathological findings of neuronal tauopathy. The characteristic sleep disorder occurs in most patients, but other neurological symptoms are also important because they can be the presenting and most disabling problem and mimic other conditions. This review focuses on nonsleep neurological symptoms and presentations of anti-IgLON5 disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000677DOI Listing
January 2019
1 Read

Continuous glucose monitoring can disclose glucose fluctuation in advanced Parkinsonian syndromes.

Authors:
Hiroyuki Todo

Neurol Int 2018 Dec 20;10(4):7921. Epub 2018 Dec 20.

Department of Neurology, National Hospital Organization Hyogo-Chuo National Hospital, Sanda, Japan.

Continuous glucose monitoring (CGM) is a method to examine glucose concentration in subcutaneous interstitial fluid sequentially. CGM can disclose glucose fluctuation (GF), which can be unrecognized in routine blood tests. A limited number of studies suggest advanced Parkinsonian syndromes (PS) is at risk of GF, however, the report of CGM in PS is scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/ni.2018.7921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322050PMC
December 2018
1 Read

Slow saccades in cerebellar disease.

Cerebellum Ataxias 2019 17;6. Epub 2019 Jan 17.

1Neurological Institute, University Hospitals, Cleveland, OH USA.

Eye movements are frequently considered diagnostic markers indicating involvement of the cerebellum. Impaired amplitude of saccades (saccade dysmetria), impaired gaze holding function (horizontal or downbeat nystagmus), and interrupted (choppy) pursuit are typically considered hallmarks of cerebellar disorders. While saccade dysmetria is a frequently considered abnormality, the velocity of saccades are rarely considered part of the constellation of cerebellar involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40673-018-0095-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337813PMC
January 2019

Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant.

Acta Neuropathol Commun 2019 Jan 23;7(1):10. Epub 2019 Jan 23.

Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Pathogenic mutations in the tau gene (microtubule associated protein tau, MAPT) are linked to the onset of tauopathy, but the A152T variant is unique in acting as a risk factor for a range of disorders including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). In order to provide insight into the mechanism by which A152T modulates disease risk, we developed a novel mouse model utilizing somatic brain transgenesis with adeno-associated virus (AAV) to drive tau expression in vivo, and validated the model by confirming the distinct biochemical features of A152T tau in postmortem brain tissue from human carriers. Specifically, Tau-AAV mice exhibited increased tau phosphorylation that unlike animals expressing the pathogenic P301L mutation remained localized to the soluble fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-019-0661-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345061PMC
January 2019
1 Read

Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?

Mov Disord Clin Pract 2018 Nov-Dec;5(6):603-606. Epub 2018 Nov 8.

Department of Neurology Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.

Background: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease with a broad clinical spectrum. It can initially be mistaken for other neurodegenerative diseases. Diagnosis of PSP earlier in the course may reduce its psychological and financial burden, permit earlier access to neuroprotective interventions, and avoid unnecessary diagnostic and therapeutic measures. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/mdc3.12678
Publisher Site
http://dx.doi.org/10.1002/mdc3.12678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277372PMC
November 2018
3 Reads

Tau PET imaging in neurodegenerative tauopathies-still a challenge.

Mol Psychiatry 2019 Jan 11. Epub 2019 Jan 11.

Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. Related tauopathies include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Down's syndrome (DS), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-specific ligands for use with positron emission tomography (PET), including first- (e. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41380-018-0342-8
Publisher Site
http://dx.doi.org/10.1038/s41380-018-0342-8DOI Listing
January 2019
10 Reads

Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study.

Neurol Neurochir Pol 2019 Jan 8. Epub 2019 Jan 8.

Department of Neurology, Medical University of Warsaw, 8 Kondratowicza str, 03-242 Warsaw, Poland.

Clinical Rationale For The Study: Autonomic nervous system (ANS) involvement in different parkinsonian syndromes has been frequently discussed. It is well established in multiple system atrophy (MSA), whereas it is less evident in progressive supranuclear palsy (PSP).

Aims Of The Study: The aims were to assess the presence and pattern of ANS involvement in MSA and PSP using noninvasive tests i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/PJNNS.a2019.0005DOI Listing
January 2019
1 Read

Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish.

Front Cell Dev Biol 2018 20;6:163. Epub 2018 Dec 20.

PROTECT, INSERM U1141, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Microtubule-associated protein tau (MAPT) hyperphosphorylation and aggregation, are two hallmarks of a family of neurodegenerative disorders collectively referred to as tauopathies. In many tauopathies, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP) and Pick's disease, tau aggregates are found associated with highly sulfated polysaccharides known as heparan sulfates (HSs). In AD, amyloid beta (Aβ) peptide aggregates associated with HS are also characteristic of disease. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fcell.2018.00163
Publisher Site
http://dx.doi.org/10.3389/fcell.2018.00163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306439PMC
December 2018
4 Reads

Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study.

Cerebellum 2019 Jan 8. Epub 2019 Jan 8.

Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

Falls in patients with neurodegenerative diseases (NDDs) have enormous detrimental consequences. A better understanding of the interplay between physical activity (PA) and fall risk might help to reduce fall frequency. We aimed to investigate the association between sensor-based PA and fall risk in NDDs, using "falls per individual PA exposure time" as a novel measure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12311-018-1002-xDOI Listing
January 2019
3 Reads

A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response.

Acta Neuropathol Commun 2019 Jan 3;7(1). Epub 2019 Jan 3.

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute (K1.24), 5 Cutcombe Road, London, SE5 9RX, UK.

Human tauopathies including Alzheimer's disease, progressive supranuclear palsy and related disorders, are characterized by deposition of pathological forms of tau, synaptic dysfunction and neuronal loss. We have previously identified a pathogenic C-terminal tau fragment (Tau35) that is associated with human tauopathy. However, it is not known how tau fragmentation affects critical molecular processes in cells and contributes to impaired physiological function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-018-0651-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318896PMC
January 2019

Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy.

J Neurol Neurosurg Psychiatry 2018 Dec 31. Epub 2018 Dec 31.

Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology, London, UK

Background: Development of autonomic failure is associated with more rapid disease course and shorter survival in patients with Parkinson's disease and multiple system atrophy. However, autonomic symptoms have not been specifically assessed as a prognostic factor in progressive supranuclear palsy (PSP). We evaluated whether development of autonomic symptoms is associated with disease progression and survival in PSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2018-319374DOI Listing
December 2018
3 Reads

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.

Alzheimers Dement (N Y) 2018 17;4:746-755. Epub 2018 Dec 17.

Global R&D Partners, LLC, San Diego, CA, USA.

Introduction: Extracellular tau is hypothesized to mediate the onset and progression of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and a subset of frontotemporal lobar degenerations. A putative strategy for treating these disorders is to reduce extracellular tau levels using tau-directed immunotherapy. The results of the first-in-human study of BIIB092 (formerly BMS-986168/IPN007), a humanized monoclonal antibody that binds to N-terminal tau, are reported here. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trci.2018.10.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298197PMC
December 2018

Tau immunoreactivity in peripheral tissues of human aging and select tauopathies.

Neurosci Lett 2018 Dec 21;696:132-139. Epub 2018 Dec 21.

Banner Sun Health Research Institute, Sun City, AZ, United States.

Many studies have been directed at understanding mechanisms of tau aggregation and therapeutics, nearly all focusing on the brain. It is critical to understand the presence of tau in peripheral tissues since this may provide new insights into disease progression and selective vulnerability. The current study sought to determine the presence of select tau species in peripheral tissues in elderly individuals and across an array of tauopathies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2018.12.031DOI Listing
December 2018
4 Reads

Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.

Mov Disord 2018 Dec 21. Epub 2018 Dec 21.

Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini-CTO, Milan, Italy.

Background: Although several studies have suggested that abnormalities in gut microbiota may play a critical role in the pathogenesis of PD, data are still extremely heterogeneous.

Methods: 16S gene ribosomal RNA sequencing was performed on fecal samples of 350 individuals, subdivided into idiopathic PD (n = 193, of whom 39 were drug naïve) stratified by disease duration, PSP (n = 22), MSA (n = 22), and healthy controls (HC; n = 113). Several confounders were taken into account, including dietary habits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27581DOI Listing
December 2018
9 Reads

Visual Search in Progressive Supranuclear Palsy.

Curr Top Behav Neurosci 2018 Dec 21. Epub 2018 Dec 21.

South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital, Middlesbrough, UK.

Progressive supranuclear palsy is often considered a disease of the motor system and is characterised by a profound oculomotor impairment. The oculomotor system is also known to be fundamentally important in cognitive processes such as attention and working memory, but the way in which these functions are affected by PSP is not well understood. In this chapter we outline the pathology and typical presentation of PSP, with a focus on the oculomotor impairment, briefly outline the role of the oculomotor system in spatial cognition and discuss some key studies examining spatial attention and memory in PSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/7854_2018_72DOI Listing
December 2018

Chronic meningoencephalitis with mixed pathology mimics progressive supranuclear palsy.

BMJ Case Rep 2018 Nov 28;11(1). Epub 2018 Nov 28.

Departments of Neurology and Pathology, Oregon Health & Science University, Portland, Oregon, USA.

We report a case of a progressive supranuclear palsy-like phenotype with rapidly progressive dementia and prominent language and executive dysfunction. Pathological examination revealed no midbrain or white matter tauopathy, but rather chronic meningoencephalitis and other mixed pathology. The cerebrospinal fluid (CSF) in this case showed a novel antibody against central nervous system and renal tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227119DOI Listing
November 2018

In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: A proton MR spectroscopy study.

Parkinsonism Relat Disord 2018 Dec 11. Epub 2018 Dec 11.

Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Neuroscience Research Centre, Magna Græcia University, Catanzaro, Italy. Electronic address:

Introduction: Several structural and functional neuroimaging studies have shown that the Supplementary Motor Area (SMA) is affected by tau pathology in patients with Progressive Supranuclear Palsy (PSP). The aim of the study was to investigate the biochemical profile of SMA in PSP patients, using proton magnetic resonance spectroscopy (H-MRS).

Methods: Sixteen PSP patients and 18 healthy controls participated in this study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183053
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.12.008DOI Listing
December 2018
6 Reads

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.

Acta Neuropathol 2019 Feb 13;137(2):279-296. Epub 2018 Dec 13.

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Göteborgsvägen 31, House V3/SU, 43180, Mölndal, Sweden.

Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer's disease (AD). Most of tau in CSF is present as fragments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-018-1948-2DOI Listing
February 2019
10 Reads

Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP.

Transl Psychiatry 2018 Dec 13;8(1):265. Epub 2018 Dec 13.

Department of Psychiatry, Washington University School of Medicine, 660S. Euclid Ave. Campus Box 8134, St. Louis, MO, 63110, USA.

Mutations in the microtubule-associated protein tau (MAPT) gene cause autosomal dominant frontotemporal lobar degeneration with tau inclusions (FTLD-tau). MAPT p.R406W carriers present clinically with progressive memory loss and neuropathologically with neuronal and glial tauopathy. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41398-018-0319-z
Publisher Site
http://dx.doi.org/10.1038/s41398-018-0319-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293323PMC
December 2018
15 Reads

Imaging in the diagnosis of progressive supranuclear palsy.

J Neurol 2019 Feb;266(2):545-547

Department of Neurology, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, CF14 4XW, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00415-018-9148-5
Publisher Site
http://dx.doi.org/10.1007/s00415-018-9148-5DOI Listing
February 2019
6 Reads

Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy.

Ann Indian Acad Neurol 2018 Oct-Dec;21(4):345-346

Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/aian.AIAN_242_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238564PMC
December 2018
10 Reads

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

JAMA Neurol 2018 Dec 3. Epub 2018 Dec 3.

Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

Importance: Neuronal and axonal destruction are hallmarks of neurodegenerative diseases, but it is difficult to estimate the extent and progress of the damage in the disease process.

Objective: To investigate cerebrospinal fluid (CSF) levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders (determined by clinical criteria and autopsy), and determine its association with longitudinal cognitive decline.

Design, Setting, And Participants: In this case-control study, we investigated NFL levels in CSF obtained from controls and patients with several neurodegenerative diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2018.3746DOI Listing
December 2018
3 Reads

The applause sign in frontotemporal lobar degeneration and related conditions.

J Neurol 2019 Feb 1;266(2):330-338. Epub 2018 Dec 1.

Neurologische Klinik und Poliklinik, Ludwig Maximilians Universität München, Munich, Germany.

The applause sign, i.e., the inability to execute the same amount of claps as performed by the examiner, was originally reported as a sign specific for progressive supranuclear palsy (PSP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-018-9134-yDOI Listing
February 2019
13 Reads
3.377 Impact Factor

Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases.

Parkinsonism Relat Disord 2018 Nov 20. Epub 2018 Nov 20.

Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan; Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan. Electronic address:

Introduction: There is still a substantial unmet need for blood-based biomarkers to make an objective diagnosis of Parkinson's disease (PD) and the parkinsonism-plus syndromes. This study is aimed to determine whether enumeration of brain-derived exosomes (BDEs) in plasma is informative in the diagnosis of those diseases.

Methods: We have developed a specific method to enumerate the plasma levels of neuron-derived, astrocyte-derived, and oligodendrocyte-derived exosomes (NDEs, ADEs and ODEs, respectively), and quantified them individually in patients with PD (n = 15), multiple system atrophy (MSA, n = 15), progressive supranuclear palsy (PSP, n = 7) and disease controls (n = 15). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.11.021DOI Listing
November 2018
2 Reads

Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis.

Parkinsonism Relat Disord 2018 Nov 5. Epub 2018 Nov 5.

Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA.

The proper diagnosis of parkinsonian disorders usually involves three steps: identifying core features of parkinsonism; excluding other causes; and collating supportive evidence based on clinical signs or investigations. While the recognition of cardinal parkinsonian features is usually straightforward, the appreciation of clinical features suggestive of specific parkinsonian disorders can be challenging, and often requires greater experience and skills. In this review, we outline the clinical features that are relevant to the differential diagnosis of common neurodegenerative parkinsonian disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183048
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.005DOI Listing
November 2018
9 Reads

Swedish Version of the Hayling Test: Clinical Utility in Frontotemporal Dementia Syndromes.

J Int Neuropsychol Soc 2019 Feb 3;25(2):195-203. Epub 2018 Dec 3.

4Clinical Memory Research Unit, Department of Clinical Sciences Malmö,Lund University,Lund,Sweden.

Objectives: The aim of this study was to assess the psychometric properties of a Swedish version of the Hayling test (HT-S) and its clinical utility in a group of patients with different frontotemporal dementia (FTD) syndromes. Early diagnosis of FTD is a challenge and requires a broad arsenal of assessment methods, neuropsychological tests not the least. The Hayling test assesses executive functions including initiation, efficiency and response inhibition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1355617718001030DOI Listing
February 2019

Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders.

Parkinsonism Relat Disord 2018 Nov 26. Epub 2018 Nov 26.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA; Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA; Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.

Introduction: Cognitive dysfunction is common in progressive supranuclear palsy (PSP) but its effect on medical decision-making has not been well studied. To address this gap in the research literature, we compared the medical decision-making capacity of patients with PSP to groups of patients with other neurodegenerative disorders. We also investigated the cognitive correlates of medical decision-making in our PSP sample. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183051
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.022DOI Listing
November 2018
10 Reads

Normal and pathological neuronal distribution of the human mesencephalic locomotor region.

Mov Disord 2019 Feb 28;34(2):218-227. Epub 2018 Nov 28.

Sorbonne University, Univ. Pierre & Marie Curie Paris 06, Cnrs, Inserm, AP-HP Pitié-Salpêtrière hospital, Brain and Spinal Cord Institute, Paris, France.

Background: Deep brain stimulation of the pedunculopontine nucleus has been performed to treat dopamine-resistant gait and balance disorders in patients with degenerative diseases. The outcomes, however, are variable, which may be the result of the lack of a well-defined anatomical target.

Objectives: The objectives of this study were to identify the main neuronal populations of the pedunculopontine and the cuneiform nuclei that compose the human mesencephalic locomotor region and to compare their 3-dimensional distribution with those found in patients with Parkinson's disease and progressive supranuclear palsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27578DOI Listing
February 2019

Falls in frontotemporal dementia and related syndromes.

Handb Clin Neurol 2018 ;159:195-203

Brain and Mind Centre, University of Sydney Medical School, Sydney, NSW, Australia.

Frontotemporal dementia (FTD) and related diseases are important causes of younger-onset dementia. Falls may be a source of morbidity and mortality in FTD, but remain underreported, and very few high-quality studies have been performed. In this chapter, we briefly review the clinical features of FTD and related syndromes such as motor neuron disease (MND) and atypical parkinsonian syndromes, such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-63916-5.00012-4DOI Listing
January 2018
2 Reads

Track density imaging in progressive supranuclear palsy: A pilot study.

Hum Brain Mapp 2018 Nov 26. Epub 2018 Nov 26.

Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy.

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by white matter (WM) changes in different supra- and infratentorial brain structures. We used track density imaging (TDI) to characterize WM microstructural alterations in patients with PSP-Richardson's Syndrome (PSP-RS). Moreover, we investigated the diagnostic utility of TDI in distinguishing patients with PSP-RS from those with Parkinson's disease and healthy controls (HC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hbm.24484DOI Listing
November 2018
1 Read

MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

Mov Disord 2019 Jan 23;34(1):105-113. Epub 2018 Nov 23.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Elevated uptake of the [ F]AV-1451 tau-PET ligand has been observed cross-sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [ F]AV-1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361527PMC
January 2019
24 Reads
5.680 Impact Factor

Progressive Supranuclear Palsy-like Syndrome from Possible Cerebral Amyloid Angiopathy.

Can J Neurol Sci 2019 Jan 20;46(1):132-136. Epub 2018 Nov 20.

Division of Neurology, Department of Medicine,University of Alberta,Edmonton, Alberta,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2018.367DOI Listing
January 2019
7 Reads

Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead.

Front Neurosci 2018 2;12:798. Epub 2018 Nov 2.

Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.

Neurofibrillary pathology comprised of pathological tau protein is closely tied to a range of neurodegenerative disorders, the most common of which is Alzheimer's disease. While they are individually rarer, a range of other disorders, the tauopathies (including Pick's disease, progressive supranuclear palsy, corticobasal degeneration, primary progressive aphasia, and ∼50% of behavioral variant frontotemporal dementia cases) display pronounced underlying tau pathology. In all cases, the distribution and amount of tau pathology closely correlates with the severity and phenotype of cognitive impairment, and with the pattern and degree of brain atrophy. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fnins.2018.00798
Publisher Site
http://dx.doi.org/10.3389/fnins.2018.00798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224648PMC
November 2018
8 Reads

A Review: Mealtime Difficulties following Frontotemporal Lobar Degeneration.

Dement Geriatr Cogn Disord 2018 13;46(5-6):285-297. Epub 2018 Nov 13.

Centre for Neuroscience of Speech, The University of Melbourne, Melbourne, Victoria,

Background: Frontotemporal lobar degeneration (FTLD) can result in a decline in behavior, language, and motor function. Mealtime disturbances are a common and significant outcome of FTLD. Disturbances during mealtimes can arise from dysphagia or may occur secondary to behavioral changes such as rapid eating, mealtime rigidity, and altered diet preferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494210DOI Listing
November 2018
3 Reads

Review: Fluid biomarkers for frontotemporal dementias.

Neuropathol Appl Neurobiol 2019 Feb 3;45(1):81-87. Epub 2018 Dec 3.

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.

Frontotemporal dementias (FTDs) are clinically, genetically and pathologically heterogeneous neurodegenerative disorders that affect the frontal and anterior temporal lobes of the brain. They are relatively common causes of young-onset dementia and usually present with behavioural disturbance (behavioural variant FTD) or language impairment (primary progressive aphasia), but there is also overlap with motor neurone disease and the atypical parkinsonian disorders, corticobasal syndrome and progressive supranuclear palsy. At post mortem, neuronal inclusions containing tau, TDP-43 or infrequently FUS protein are seen in most cases. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/nan.12530
Publisher Site
http://dx.doi.org/10.1111/nan.12530DOI Listing
February 2019
11 Reads

Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders.

Parkinsonism Relat Disord 2018 Oct 6. Epub 2018 Oct 6.

Department of Neurology, Santa Maria University Hospital, Terni, Italy.

To establish a clinical diagnosis of a parkinsonian disorder, physicians rely on their ability to identify relevant red flags, in addition to cardinal features, to support or refute their working diagnosis in an individual patient. The term 'red flag', was originally coined in 1989 to define the presence of non-cardinal features that may raise a suspicion of multiple system atrophy (MSA), or at least suggest alternative diagnosis to Parkinson's disease (PD). Since then, the term 'red flag', has been consistently used in the literature to denote the clinical history or signs that may signal to physicians the possibility of an atypical parkinsonian disorder (APD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.10.009DOI Listing
October 2018
5 Reads